Sickle Cell
Protocol:GBT440-031
Condition or Disease: Sickle Cell Disease
Study Type: Interventional (Clinical Trial)
Status: Enrollment Paused
Study Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Subjects with Sickle Cell Disease
Principal I investigator: Alan Ikeda, MD
More Info: //clinicaltrials.gov/ct2/show/NCT03036813
